<DOC>
	<DOCNO>NCT02587819</DOCNO>
	<brief_summary>This Phase 1 , open-label , single-arm , multicenter study assess safety tolerability BSCT ( anti-nf-P2X7 ) 10 % Ointment subject BCC .</brief_summary>
	<brief_title>Investigation Safety Tolerability BSCT ( Anti-nf-P2X7 ) 10 % Ointment</brief_title>
	<detailed_description>The purpose trial determine safety tolerability BSCT ( anti-nf-P2X7 ) 10 % Ointment topically apply twice daily 28 consecutive day male female patient BCC ; determine steady-state pharmacokinetics ( PK ) active pharmaceutical ingredient ( total sheep Immunoglobulin G [ IgG ] ) BSCT ( anti-nf-P2X7 ) 10 % Ointment apply twice daily BCC lesion . This open-label , single-arm , multicenter Phase 1 study enrol 21 BCC patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Male female adult â‰¥ 18 year age ; One primary histologically confirm BCC lesion , locate hand foot , suitable surgical excision , minimum area 0.5 cm2 maximum diameter 2.0 cm ( histological diagnosis make 4 week prior Screening visit . Willing refrain use nonapproved lotion cream BCC treatment site surround area treatment period wash treated area least 8 hour follow application study medication ; Ability follow study instruction likely complete study requirement ; Written inform consent obtain , include consent biopsy tissue examine stored central dermatopathologist ; Written consent allow photograph BCC lesion use part study data ; For female childbearing potential , negative pregnancy test Screening use acceptable form birth control . Pregnant , lactating , plan pregnancy study ; Presence know suspected systemic cancer ; Histological evidence squamous cell carcinoma ( SCC ) tumor BCC biopsy specimen ; Histological evidence severe squamous metaplasia , infiltrative , desmoplastic , micronodular growth pattern biopsy specimen ; Evidence dermatological disease confound skin condition within 25cm2 treatment area , eg , SCC , actinic keratosis , rosacea , psoriasis , atopic dermatitis , eczema , xeroderma pigmentosa ; Concurrent disease treatment suppress immune system ; Chronic medical condition judgment investigator would interfere performance study would place patient undue risk ; Known sensitivity ingredient study medication ; Treatment systemic chemotherapeutic agent ( eg , methotrexate , paclitaxel ) within 6 month prior Baseline visit ; Use systemic retinoids within 6 month prior Baseline visit ; Treatment systemic immunomodulators immunosuppressant within 6 month prior Baseline visit ; Use topical immunomodulators within 2 cm target treatment area within 4 week prior Baseline visit ; Treatment topical agent treatment BCC actinic keratosis within 2 cm target treatment area within 4 week prior Baseline visit : Treatment liquid nitrogen , surgical excision curettage within 2 cm target treatment area 4 week prior Baseline visit ; Clinically significant abnormality note screen ECG , physical examination , laboratory test result ; Evidence current chronic alcohol drug abuse , investigator 's opinion , might interfere subject 's adherence protocol requirement ; Current enrollment investigational drug device study participation study within 4 week Baseline visit ; In investigator 's opinion , evidence unwillingness , inability follow restriction protocol complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>